CVALF OTC

Covalon Technologies Ltd. is a global medical technology firm specializing in the innovation, production, commercialization, and licensing of medical solutions across the United States, Canada, Europe, the Middle East, Asia, and Latin America. The company's operations are built upon three distinct proprietary technological platforms. The first, a collagen matrix platform, underpins a family of products aimed at treating chronic and infected wounds such as diabetic, pressure, and venous ulcers, as well as donor/graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first- and second-degree burns. Secondly, an antimicrobial silicone adhesive platform is utilized in various pre- and post-surgical and vascular access products, specifically engineered to eliminate bacteria or yeast on contact, thus providing broad-spectrum antimicrobial activity. The third is a medical coating platform, an advanced process employing photo-polymerization to create active grafting sites where new polymer chains are initiated and propagate from the surface of existing medical devices. Covalon's product offerings include wound care dressings, surgical and peri-operative solutions, and infection management tools. These products, sold under the Covalon brand, are distributed through both the company's direct sales force and third-party networks to a wide range of clients, including hospitals, wound and burn care centers, acute and extended care facilities, home health agencies, and physicians' offices. The company's corporate headquarters are located in Mississauga, Canada.